Abstract
Differences in methods for biospecimen collection, processing, and storage can yield considerable variability and error. Therefore, best practices for standard operating procedures are critical for successful discovery, development, and validation of disease biomarkers. Here, we describe standard operating procedures developed for biospecimen collection during the DREAM (Diabetes RElated to Acute pancreatitis and its Mechanisms) Study within the Type 1 Diabetes in Acute Pancreatitis Consortium. Notably, these protocols were developed using an integrative process based on prior consortium experience and with input from working groups with expertise in immunology, pancreatitis, and diabetes. Publication and adoption consistent biospecimen protocols will inform future studies and allow for better comparisons across different metabolic research efforts.
Original language | English |
---|---|
Pages (from-to) | 593-597 |
Number of pages | 5 |
Journal | Pancreas |
Volume | 51 |
Issue number | 6 |
DOIs | |
State | Published - Jul 1 2022 |
Bibliographical note
Publisher Copyright:© Wolters Kluwer Health, Inc. All rights reserved.
Funding
D.K.A. is part of advisory board for National Pancreas Foundation and American Pancreatic, Association Foundation and receives royalties from McGraw-Hill. M.D.B receives research support from Viacyte and Dexcom and is part of advisory board for Insulet. P.J.L. is part of advisory board for AbbVie. R.E.P. has consulting activities with Bayer AG, Corcept Therapeutics Incorporated, Dexcom, Gasherbrum Bio, Inc, Hanmi Pharmaceutical Co, Hengrui (USA) Ltd, Merck, Novo Nordisk, Pfizer, Rivus, Pharmaceuticals, Inc, Sanofi, Scohia Pharma, Inc, and Sun Pharmaceutical Industries; receives research support from Hanmi Pharmaceutical Co, Janssen, Metavention, Novo Nordisk, Poxel, SA, and Sanofi; and receives speaking fees from Novo Nordisk. E.K.S. receives speaking fees from MedScape. C.S. is part of advisory board for Vertex Pharmaceuticals. The other authors declare no conflict of interest. The study was supported by funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) for the Type 1 Diabetes in Acute Pancreatitis Consortium (T1DAPC) under award numbers: U01 DK127367 (Minnesota), U01 DK127377 (Pittsburgh), U01 DK127378 (Illinois at Chicago), U01 DK127382 (Indiana), U01 DK127384 (DCC, Penn State), U01 DK127388 (Ohio State), U01 DK127392 (University of Florida–Advent Health), U01 DK127395 (Stanford), U01 DK127400 (Johns Hopkins), U01 DK127403 (Cedars-Sinai), and U01 DK 127404 (Benaroya-Seattle).
Funders | Funder number |
---|---|
Corcept Therapeutics Incorporated | |
Hanmi Pharmaceutical Co., Ltd. | |
National Institute of Diabetes and Digestive and Kidney Diseases | U01 DK127392, U01DK127377, U01 DK127367, U01 DK127378, U01 DK127388, U01 DK127382, U01 DK127384 |
National Institute of Diabetes and Digestive and Kidney Diseases | |
Florida AandM University and Florida State University | U01 DK127400, U01 DK127395 |
Florida AandM University and Florida State University | |
The Johns Hopkins University | U01 DK127403 |
The Johns Hopkins University | |
Cedars-Sinai Medical Center | U01 DK 127404 |
Cedars-Sinai Medical Center |
Keywords
- AP - acute pancreatitis
- CPDPC - Chronic Pancreatitis Diabetes Pancreas Cancer Consortium
- DCC - data coordinating center
- DKCR - NIDDK Central Repository
- DREAM - Diabetes RElated to Acute pancreatitis and its Mechanisms
- LN - liquid nitrogen
- NIDDK - National Institute of Diabetes and Digestive and Kidney Diseases
- PBMC - peripheral blood mononuclear cells
- SOP - standard operating procedures
- ST - sample tracking module
- T1DAPC - Type 1 Diabetes in Acute Pancreatitis Consortium
- biorepository
- biosamples
- immunology
- laboratory protocol
- pancreas
- type 1 diabetes
ASJC Scopus subject areas
- Internal Medicine
- Endocrinology, Diabetes and Metabolism
- Hepatology
- Endocrinology